Study of Blood Biomarker Signatures to Detect Early Gastric Preneoplasia and Cancer in Adults

What this Trial Is About

This research aims to identify and confirm a set of blood-based biomarkers in plasma that are linked to early changes in the stomach lining known as gastric preneoplasia. It compares patients who already have gastric lesions with healthy individuals. Gastric cancer is a common and serious disease worldwide, often diagnosed late due to invasive methods like endoscopy. Early detection through blood tests could improve prevention, monitoring, and treatment outcomes. The study builds on previous findings of protein signatures related to inflammation and cancer development in the stomach. Participants include patients with various gastric lesions such as glandular atrophy, intestinal metaplasia, dysplasia, and early-stage gastric adenocarcinoma, as well as healthy volunteers without stomach conditions. Blood samples of about 9 to 10 mL will be collected either during routine care or specifically for this research. The study will measure protein levels in plasma to validate and improve the prediction of early stomach changes and cancer risk across different lesion types and severities. During the study, participants will provide blood samples which will be analyzed using immuno-based methods to detect the protein signatures. Researchers will evaluate how these signatures relate to different stages of gastric lesion development over 30 months. The main outcome is to validate a protein signature associated with gastric mucosal dysplasia compared to healthy controls. Secondary outcomes include similar validations for other lesion types and cancer stages. The study involves no treatment intervention and focuses on biomarker discovery and validation.

Circulating Biomarker Signatures for the Detection of Gastric Preneoplasia and Cancer